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Abstract
Purpose—To identify factors associated with the visual acuity outcome following focal/grid
photocoagulation for diabetic macular edema (DME) among eyes randomized to the focal/grid
photocoagulation treatment group within the Diabetic Retinopathy Clinical Research Network
(DRCR.net) trial comparing triamcinolone with focal/grid laser.
Design—Multicenter, randomized clinical trial.
Participants—Three hundred thirty eyes with DME assigned to the focal/grid photocoagulation
group, visual acuity 20/40 to 20/320 and optical coherence tomography (OCT) central subfield
thickness ≥250 microns.
Methods—Eyes were treated with a protocol-defined photocoagulation technique, which was
repeated at 4-month intervals for persistent or recurrent edema. Separate logistic regression models
were used to evaluate the associations of demographic, clinical, OCT, and fundus photographic
variables with visual acuity improvement or worsening of 10 or more letters from baseline to 2 years.
The association of the initial visual acuity outcome after treatment with the subsequent visual acuity
course also was evaluated.
Main Outcome Measures—Visual acuity measured with the electronic Early Treatment Diabetic
Retinopathy Study method.
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Results—Worse baseline visual acuity was the only factor found to be associated with more
frequent visual acuity improvement (P<0.001), and both greater baseline OCT-measured retinal
volume (P=0.001) and better baseline visual acuity (P=0.009) were found to be associated with more
frequent visual acuity worsening. Visual acuity outcomes were similar in eyes with and without prior
macular or panretinal photocoagulation. The initial visual acuity outcome at 4 months was not
generally predictive of the subsequent course. Many eyes that worsened 10 or more letters from
baseline to 4 months subsequently improved, and many eyes that initially improved, subsequently
worsened.
Conclusions—At this time, focal/grid photocoagulation remains the standard management for
DME and these results do not alter this paradigm.
Introduction
Despite recent attempts at strict glycemic control and optimization of other important systemic
parameters such as hypertension and hyperlipidemia, diabetic retinopathy continues to be a
leading cause of new onset vision loss worldwide in the working age population.1-3 Although
severe vision loss can occur from proliferative diabetic retinopathy, diabetic macular edema
(DME) accounts for the majority of vision loss.4, 5 The Early Treatment Diabetic Retinopathy
Study (ETDRS) demonstrated the efficacy of focal/grid photocoagulation in reducing the risk
of moderate vision loss from DME.6 However, in the two decades since the completion of
ETDRS, diabetic patient care approaches have evolved substantially.1 The beneficial outcomes
of focal/grid laser in an era of improved glycemic control were confirmed and expanded in
recent clinical trials conducted by the Diabetic Retinopathy Clinical Research Network
(DRCR.net).7, 8 At this time, no ocular treatment for DME has been demonstrated to have a
better long-term outcome than focal/grid photocoagulation.
In an effort to identify factors associated with the visual acuity outcome following focal/grid
photocoagulation for DME, we performed additional analyses on the 330 eyes that were
randomized to the laser group of a multicenter, randomized clinical trial comparing focal/grid
photocoagulation with intravitreal triamcinolone.
Methods
Of the 840 eyes (of 693 subjects) enrolled in the DRCR.net “Randomized Trial Comparing
Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular
Edema”, 330 eyes (one eye of 330 subjects) were randomly assigned to focal/grid
photocoagulation. These eyes form the cohort evaluated in the current report. The primary trial
outcome was assessed at two years. The detailed methods of this study have been published
previously, 8, 9 with the full protocol available at www.drcr.net (Accessed August 26, 2009).
Briefly, the trial was designed to determine whether visual acuity at 2 years was better in eyes
with center-involved DME treated with intravitreal preservative-free triamcinolone (1 mg or
4 mg) as compared with focal/grid laser. Individuals were eligible if they were 18 years of age
or older with type 1 or 2 diabetes. Study eye eligibility criteria included best corrected electronic
ETDRS visual acuity letter score between 73 and 24 (approximate Snellen equivalents
20/40-20/320), macular edema on exam involving the fovea, optical coherence tomography
(OCT) central subfield thickness ≥ 250 microns, and no prior or anticipated need for scatter
photocoagulation for proliferative diabetic retinopathy (PDR) within 4 months of the baseline
study visit. Patients were ineligible if they had undergone any prior treatment with intravitreal
corticosteroids or pars plana vitrectomy, recent treatment with peribulbar corticosteroids or
laser photocoagulation, or a history of glaucoma or treatment for steroid-induced intraocular
pressure elevation.
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Focal/grid photocoagulation was performed at baseline by the treatment technique described
in Table 1. This technique is modified from the published ETDRS protocol to be representative
of the technique in most common use today as determined by a survey of DRCR.net
investigators and is referred to as focal/grid photocoagulation.10-14 Retreatment was
performed at 4-month intervals for persistent or recurrent DME unless one or more of the
following deferral criteria were met: (1) OCT central subfield of 225 μm or less, visual acuity
score >= 79 (approximate Snellen equivalent of ∼20/25), or substantial improvement in
macular edema (>= 50% decrease in OCT central subfield thickening) with expectation of
further improvement without additional laser; (2) contraindication to further laser based on an
adverse event from previous laser or the investigator's judgment that maximum safe laser
already had been performed; or (3) apparent futility of additional laser as defined by at least
an 8-month period over which laser was given twice with less than a 5 letter improvement in
the visual acuity score and lack of decrease in OCT central subfield thickness of at least 50
microns, representing at least a 20% reduction in retinal thickening. An eye assigned to the
laser group could receive alternative treatment (e.g., intravitreal triamcinolone) if it
experienced at least a 15 letter decrease from baseline in best corrected visual acuity that was
sustained over 2 consecutive 4 month intervals and if the decrease was due to OCT-documented
persistent or recurrent macular edema. Forty three (13%) of the 330 eyes received treatment
for DME other than laser (study intravitreal triamcinolone, nonstudy triamcinolone [Kenalog],
vitrectomy, or bevacizumab) within the two-year period.
Statistical Methods
Separate logistic regression models were used to evaluate the association of baseline clinical,
OCT, and fundus photographic variables (see tables 2-5 for listing of variables evaluated) with
visual acuity improvement (10 or more letters) or worsening (10 or more letters) from baseline
to 2 years. Factors with a p value <0.10 were evaluated in multivariate models, with a final
model consisting of factors with a p value <0.01 following a backwards selection process. The
last-observation-carried forward method was used for imputation when the 2-year visual acuity
score was missing. Similar results were produced when analyses were limited to subjects who
completed the two year exam.
All reported P values are two-sided and unadjusted for multiple comparisons. In view of the
large number of variables evaluated, only associations with p values <0.01 were considered
unlikely to be due to chance. Statistical analyses were conducted utilizing SAS software,
version 9.1 (SAS Institute Inc., Cary, NC).
Results
Mean age of the 330 subjects was 63 years; 50% were women and 74% Caucasian. Type 1
diabetes was present in 4% and type 2 diabetes in 96%. Prior macular photocoagulation had
been performed in 198 (60%) of the eyes.
Two-year follow up was completed by 272 (82%) of the 330 subjects. Among the 58 subjects
with incomplete follow up, 20 (34%) died prior to two years and the others either withdrew
from the study or were lost to follow up. On average, the subjects who completed two years
of follow up had 2.9±1.4 [standard deviation (SD)] focal/grid photocoagulation treatments over
the course of 2 years. The number of focal/grid photocoagulation treatments performed during
the study in the 169 subjects who had undergone macular photocoagulation prior to enrolling
in this study did not differ substantially from the number received by the 103 subjects who
were laser naïve at study entry (mean 2.8±1.3 versus 3.1±1.6, P=0.15 by t test).
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Baseline Factors and Visual Acuity Outcome
Visual acuity improved from baseline to 2 years by 10 or more letters in 32% of eyes and
worsened by 10 or more letters in 19% of eyes. Numerous factors were evaluated for their
association with improvement or worsening of visual acuity. These included demographics
and medication use (Table 2), ocular characteristics and prior laser therapy (Table 3), OCT
findings (Table 4) and photographic ocular characteristics (Table 5). In a multivariate model
(Table 6), the only factor found to be statistically significantly (p < 0.01) associated with visual
acuity improvement (10 or more letter gain from baseline) was baseline visual acuity (worse
baseline visual acuity was associated with greater improvement, P<0.001). Of note, visual
acuity improvement was not associated with baseline OCT-measured retinal thickness or with
whether macular photocoagulation or panretinal photocoagulation previously had been
received. A loss of 10 or more letters was associated in the multivariate model with baseline
OCT-measured retinal volume (greater retinal volume was associated with more frequent
visual acuity worsening, P=0.001) and baseline visual acuity (better visual acuity was
associated with more frequent visual acuity worsening, P=0.009).
Visual Acuity Outcome According to Initial Response
The proportion of eyes with a 10 or more letter improvement gradually increased over the two
years of follow up while the proportion with a 10 or more letter loss was fairly similar from 4
months to 2 years (Figure 1). At 4 months, 47 eyes (18%) had an improvement in the visual
acuity letter score ≥10 from baseline, 172 (65%) had a letter score within 9 of baseline, and 45
(17%) had a letter score ≥10 worse than baseline. As shown in Table 7, eyes that had worsened
from baseline to 4 months were more likely to improve than worsen further from 4 months to
2 years, whereas eyes that had improved or changed less than 10 letters and had visual acuity
worse than 20/32 at 4 months were about equally likely to improve or worsen by 10 letters
between four months and two years. Eyes that had visual acuity 20/32 or better at 4 months
were more likely to worsen than improve between 4 months and 2 years, as expected due to
the ceiling on achieving additional substantial improvement.
Discussion
Since focal/grid photocoagulation is the current standard care for DME, we conducted an
analysis in an attempt to identify factors associated with improvement and with worsening of
visual acuity after laser treatment. The results of these analyses were more remarkable for the
factors that were not associated with the visual acuity outcome following focal/grid
photocoagulation rather than the factors that were associated. We evaluated factors potentially
correlated with improvement and worsening separately, believing that different factors might
be associated with each direction of change. Not surprisingly, the likelihood of improving 10
or more letters (2 or more lines) was greater when baseline visual acuity was poor and the
likelihood of worsening 10 or more letters was greater when baseline visual acuity was good.
This likely reflects, at least in part, ceiling and floor effects on the amount of improvement that
can occur when acuity is only mildly reduced and the amount of worsening that can occur when
visual acuity is poor. Thicker retinas at baseline were more likely to lose vision than thinner
retinas after adjusting for visual acuity, perhaps reflective of a group of eyes with more severe
and/or longer standing disease.
Because of the large number of variables evaluated, we only considered associations with a p
value <0.01 to be significant. Nevertheless, there were few variables that even met a 0.05 p
value threshold. No demographic factors, factors related to diabetes (type, duration, HbA1c,
systolic or mean arterial blood pressure), OCT morphologic assessments (cystoids
abnormalities, subretinal fluid, vitreoretinal abnormalities) or fundus photograph assessments
(retinopathy severity, hemorrhage, microaneurysms, exudates, surface wrinkling) were
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statistically associated with the visual acuity outcome. The sample size was large and the
tightness of the confidence intervals on the point estimates of association (odds ratios) indicate
that it is unlikely that meaningful associations were undetected. Of note, the probability of
improvement was similar in eyes that had and had not received prior macular photocoagulation;
eyes that had been treated with laser 3 or more times in the past had a similar chance of visual
acuity improvement as eyes that had not had prior laser treatment. This finding suggests that
there is value in continuing to administer additional focal/grid photocoagulation as long as
edema is still present and it is possible to place additional burns. We also assessed whether
change in visual acuity at 4 months was predictive of change at two years but we could not
identify a clear pattern. Many eyes that worsened 10 or more letters from baseline to 4 months
subsequently improved and many eyes that initially improved, subsequently worsened.
The strengths of this study were the large number of DME eyes with standardized baseline
measurements, treated with a standardized focal-grid photocoagulation protocol and
prospectively followed with standardized measurements of visual acuity. This represents the
largest cohort of such eyes since the ETDRS was conducted. The two-year completion rate of
88% (excluding deaths) is less than optimal. However, analyses with and without imputation
for missing data provided similar results and there is not a clear reason to expect that the missing
data biased the results. The potential role of retinal nonperfusion could not be assessed since
flourescein angiography was not required as part of this study.
At this time, focal/grid photocoagulation is the only ocular treatment that has been
demonstrated to be effective for DME. Our results and the results from the ETDRS have not
demonstrated any subgroups of patients for whom treatment is contraindicated.
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Figure 1.
Change in visual acuity (10 letter improvement and 10 letter worsening) from baseline to each
visit through 2 years. The bars represent 95% confidence intervals.
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Table 1
Comparison of the Modified-Early Treatment Diabetic Retinopathy Study (ETDRS) and
ETDRS Focal/Grid Photocoagulation Techniques
Burn Characteristic Focal / Grid Photocoagulation (modified-
ETDRS technique)
ETDRS Technique
Area Considered for Treatment
500 to 3000 microns from the center of
macula.
Initially same. However, if vision is < 20/40 and
retinal edema/leakage persists, lesions >300
microns from the macular center are treated unless
there is perifoveal capillary dropout.
No burns are placed within 500 microns of
optic disk.
Wavelength: Green or yellow Blue-green or green
Burn Size 50 microns
Focal: 50-100 microns
Grid: <200 microns
Burn Duration 0.05 to 0.1 sec Same
Grid Treatment
If fluorescein angiography is performed:
apply to all areas of diffuse leakage or
nonperfusion within the area noted above as
well as to all areas with retinal thickening
within the area noted above Same
If fluorescein angiography is not performed:
apply to all areas with retinal thickening
within the area noted above
Burn Intensity Barely visible (light grey) “Mild” intensity (More intense than modified-ETDRS technique)
Burn Separation 2 visible burn widths apart At least 1 burn width apart
Focally Treat Leaking Microaneurysms
All leaking microaneurysms are focally
treated, but only in areas of retinal thickening
located within treatment area noted above
Same. In addition, optional treatment of focal
lesions > 3,000 microns from the center if
prominent leaks present and associated with
thickening or hard exudates extending closer to the
center
Change Microaneurysms Color Not required, but at least a mild burn shouldbe evident beneath all Microaneurysms
Recommended whitening or darkening of large
Microaneurysms (Microaneurysms > 40 microns)
ETDRS =Early Treatment Diabetic Retinopathy Study
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Table 6
Multivariate Model for 10 Letter Gain and 10 Letter Loss at 2 Years
Univariate Model P
value
Multivariate Model*P value Final Multivariate
Model†P Value
A. 10 or More Letter Improvement from
Baseline to 2 Years
Prior Panretinal Photocoagulation 0.07 0.05
Visual Acuity‡ <0.001 <0.001 <0.001
Hard Exudates in Grid (Photographic) § 0.08 0.34
Hard Exudates in Center (Photographic) § 0.04 0.25
B. 10 or More Letter Worsening from Baseline
to 2 Years
Visual Acuity‡ 0.07 0.008 0.009
OCT Retinal Volume‡ 0.01 0.006 0.001
Hemorrhages/Microaneurysms in Grid (Photographic) § 0.06 0.23
*
includes all factors that were P<0.10 in the univariate models; for factors with missing data, an indicator for missing data was added to the model
†
includes factors that remained in the multivariate model after a backward selection process using P<0.01 to stay in the model
‡
continuous version of variable used
§
ordinal version of variable used
OCT= Optical Coherence Tomography
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